Trump's week in review: SPLC indicted; marijuana reclassified; ceasefires extended

4. DOJ reclassifies marijuana as a Schedule III drug
The U.S. Department of Justice announced Thursday the immediate classification of marijuana products approved by the Food and Drug Administration, as well as products regulated under state medical marijuana programs, as Schedule III substances under the Controlled Substances Act.
The DOJ also announced plans to hold an administrative hearing on June 29 to evaluate whether marijuana should be more broadly reclassified as a Schedule III drug.
At the federal level, marijuana is currently classified as a Schedule I drug. As explained by the Drug Enforcement Administration, “Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse.” By contrast, Schedule III drugs are “defined as drugs with a moderate to low potential for physical and psychological dependence.”
“The Department of Justice is delivering on President Trump’s promise to expand Americans’ access to medical treatment options,” said Acting U.S. Attorney General Todd Blanche. “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.”
President Trump’s December 2025 executive order directed the U.S. attorney general to complete the rulemaking process required to classify marijuana as a Schedule III drug. The order stated that medical marijuana has demonstrated benefits and that its current Schedule I classification has “impeded research.”
Ryan Foley is a reporter for The Christian Post. He can be reached at: ryan.foley@christianpost.com





